See Bull Run's current company pages for Torrent Pharmaceuticals and Mankind Pharma. For a larger peer comparison, see Bull Run's Sun Pharma vs Torrent Pharma and Sun Pharma vs Mankind Pharma.

Q1 FY27 financial scorecard

Torrent's 55% growth headline needs to be normalized

This distinction is essential for valuation.

Acquisitions can create real shareholder value, but simply adding acquired revenue does not represent organic growth.

The relevant questions are:

• How quickly is the underlying business growing?
• How profitable is the acquired business?
• How much debt was required?
• What synergies are being realized?
• Will ROCE ultimately improve?

Torrent's underlying business was still exceptionally strong

The base business grew 17% to approximately ₹3,720 crore.

Operating EBITDA increased 20% to approximately ₹1,240 crore.

Base-business operating EBITDA margin reached 33.3%.

That means the Torrent story does not depend solely on acquisition accounting.

The core franchise itself is performing strongly.

JB Pharma is already more profitable than Torrent's base business

That is an unusually attractive acquired profit stream.

JB revenue grew around 10%.

Its India branded business grew around 13%.

International business, including CDMO, grew around 12%.

More importantly, cost synergies are running ahead of the original plan.

Torrent is extracting JB synergies faster than expected

Management said much of the Q1 margin expansion at JB came from cost synergies rather than temporary operating leverage.

The original first-year synergy objective had been around ₹90 crore.

Management subsequently said realization should exceed ₹100 crore.

That matters because cost synergies directly increase EBITDA without requiring equivalent revenue growth.

But integration can temporarily disrupt revenue

Torrent has begun moving selected JB brands and divisions into its own field-force structure.

This creates temporary risk.

Doctors and territories previously serviced by one medical representative must be transitioned to another.

Management expects some integration effects across the next few quarters before growth normalizes.

So Q1's clean JB growth should not automatically be extrapolated quarter by quarter.

Torrent's base India business grew 19%

This is one of the strongest operating metrics in the comparison.

The growth mix was broad:

• approximately 5.1% volume growth;
• approximately 7.7% price growth;
• approximately 6% new-product contribution.

All three components outperformed the respective market growth drivers cited by management.

Volume growth is particularly important

Indian branded-pharma growth can sometimes be dominated by annual price increases.

That is useful but less powerful than genuine prescription-volume expansion.

Torrent's 5.1% volume growth suggests doctors are prescribing more units, not merely paying higher prices.

This supports the durability of the domestic franchise.

Curatio is another growth engine

Torrent's dermatology acquisition continued growing rapidly.

Curatio revenue increased approximately 34% in Q1.

Torrent has increased field-force investment and consumer advertising around the portfolio.

If that growth remains durable, Curatio becomes another example of Torrent's acquisition-and-scale playbook.

The combined Torrent-JB franchise is now number one in cardiac

Cardiac is one of India's largest and fastest-growing chronic pharmaceutical segments.

Torrent has historically been strong in cardiology.

Adding JB's portfolio increases:

• brand depth;
• prescriber reach;
• field-force scale;
• cross-selling potential;
• therapy leadership.

Management reported combined field-force strength of approximately 9,400 after Q1.

Mankind's competitive advantage is broader prescription reach

Mankind's commercial system remains larger in physical reach.

Its broader platform includes:

• 18,500-plus field-force professionals;
• 17,600-plus stockists;
• reach to more than 500,000 doctors;
• number-one ranking by prescriptions;
• number-two ranking by covered-market volume.

Mankind's moat therefore comes less from extremely high sales productivity per representative and more from enormous market penetration.

Mankind's domestic revenue reached ₹3,426 crore

The broad domestic business grew approximately 10.5%.

Domestic pharma excluding Consumer Healthcare generated approximately ₹3,180 crore and grew 11%.

Consumer Healthcare contributed approximately ₹246 crore.

This makes India the overwhelming centre of Mankind's economics.

The India revenue comparison needs one important caveat

Mankind's ₹3,426 crore is a broad domestic figure.

Torrent's disclosed ₹2,157 crore is specifically the Torrent base India business and excludes JB Pharma.

JB's total ₹1,201 crore includes both Indian and international operations, but Torrent did not disclose a directly comparable combined India rupee number in its opening Q1 commentary.

Bull Run therefore does not manufacture a false combined domestic figure.

Mankind's chronic portfolio is becoming the main quality lever

Mankind's chronic portfolio grew approximately 15.8%.

Its chronic share excluding BSV reached around 40%.

Management wants that figure to approach 50% over the medium term.

This matters because chronic therapies can generate:

• repeat prescriptions;
• longer patient lifetimes;
• higher field-force productivity;
• more predictable demand;
• better brand durability.

Cardiac growth reached 19.4%

Mankind's cardiac franchise outperformed the broader market.

The Telmikind family grew approximately 21%.

Other cardiac brands also recorded strong double-digit growth.

This is precisely the therapy where Torrent is strongest.

Competition between the two companies is therefore becoming increasingly direct.

Anti-diabetes is another battleground

Mankind's anti-diabetes portfolio excluding specific newer-product effects grew approximately 12.7%.

Its Glizid family grew approximately 29%.

Torrent is simultaneously expanding its diabetes franchise and aggressively entering the GLP-1 opportunity.

Both companies therefore want a larger share of India's rising diabetes and obesity spending.

Torrent's semaglutide launch was extremely strong

Torrent reported approximately ₹50 crore of Q1 sales from its India semaglutide franchise.

Combined oral and injectable share reached approximately 36% under the market dataset cited by management.

The oral franchise held particularly high early share.

This demonstrates the value of Torrent's chronic-prescriber network.

But the injectable suffered a supply disruption

A manufacturing-partner issue temporarily affected certain Semalix injectable SKUs.

Torrent secured an alternative source and expected products to return during August.

The issue does not invalidate the launch.

It does show that supply reliability matters as much as physician demand in fast-growing pharmaceutical markets.

Mankind's BSV acquisition changes its specialty mix

Mankind historically won through affordability and reach.

BSV adds scientific complexity.

This can increase revenue per doctor relationship and lower dependence on mass-market acute products.

BSV versus JB Pharma represents two different M&A strategies

Torrent is deepening a business model it already understands exceptionally well.

Mankind is expanding into categories with higher scientific and manufacturing barriers than much of its historical portfolio.

Mankind's acute portfolio is recovering

Acute therapy growth improved to approximately 10.9% from about 6.1% a year earlier.

That matters because the majority of Mankind's ex-BSV portfolio is still not chronic.

A successful transition therefore requires both:

• stronger chronic growth;
• stable acute performance.

International revenue is another Mankind growth lever

International revenue increased approximately 29% to ₹605 crore.

It still represents only about 15% of consolidated revenue.

That gives Mankind significant room to diversify away from India over time.

Torrent is already more established in international branded markets such as Brazil and Germany.

Torrent's Brazil business demonstrates branded-market strength

Reported Brazil revenue grew strongly in rupees, although constant-currency primary-sales growth was weaker because of a deliberate channel inventory reduction.

Secondary-sales market data remained stronger.

This is a useful accounting lesson:

primary shipment growth can temporarily differ from underlying prescription demand.

Torrent's US business is improving—but remains small

US constant-currency revenue was approximately US$44 million.

It grew around 23% in constant currency.

Management said certain one-time opportunities contributed.

The company continues targeting sustainable US profitability during FY27.

This is not yet the central Torrent thesis.

Mankind is much less exposed to US generic volatility

Its consolidated earnings are still predominantly linked to India and selected international branded businesses.

This reduces exposure to:

• US generic price erosion;
• Paragraph IV litigation;
• limited-competition cliffs;
• large US customer concentration.

The trade-off is greater India concentration.

Margins strongly favour Torrent

Torrent's operating EBITDA margin reached 33.8%.

Mankind's margin reached 26.3%.

A 750-basis-point gap is substantial.

Torrent's high margin reflects:

• large branded-formulation mix;
• high India productivity;
• JB cost synergies;
• favourable gross margin;
• premium chronic brands.

Yet Mankind generated slightly more PAT

Mankind PAT was approximately ₹574 crore.

Torrent PAT was approximately ₹566 crore.

That looks surprising given Torrent generated ₹604 crore more EBITDA.

The explanation lies below EBITDA.

Torrent is carrying substantially larger acquisition-related financing, depreciation, amortisation and exceptional costs.

This is why EBITDA alone can mislead after acquisitions

Acquired intangible assets can increase amortisation.

Borrowed acquisition funding increases interest expense.

Integration can create exceptional charges.

So a high-EBITDA acquisition may still produce much smaller incremental PAT initially.

Investors should follow the entire earnings bridge.

Mankind's deleveraging is significantly further advanced

Mankind reported net debt around ₹3,377 crore at June 30, 2026.

Net debt to adjusted EBITDA had fallen to approximately 0.9x.

Management remains focused on repaying BSV acquisition debt by FY28.

This creates a future earnings tailwind as finance costs decline.

Torrent reported leverage of 2.07x

Torrent's combined net debt to EBITDA stood at approximately 2.07x.

This is manageable for a high-margin pharmaceutical company.

But it is more than twice Mankind's reported leverage measure.

Torrent therefore needs to convert JB's strong EBITDA into cash and delever.

ROCE does not currently reward Torrent's margin advantage

Torrent's ROE is much higher, but its leverage is also much higher.

ROCE is almost identical between the companies.

This is important because Torrent trades at a substantially higher valuation despite not currently showing a comparable premium in ROCE.

Torrent's historical free cash generation is strong

Bull Run's standardized five-year field shows approximately ₹10,547 crore of cumulative free cash flow.

Mankind's comparable field is approximately ₹5,697 crore.

Torrent therefore has a strong historical record of converting pharmaceutical profits into cash.

The next test is whether that cash conversion remains strong after JB.

Valuation is the largest advantage for Mankind

Torrent's P/E is roughly 52% higher than Mankind's.

Its price-to-book multiple is more than three times Mankind's.

That is a substantial premium.

What is Torrent's valuation paying for?

• 33%-plus operating margins;
• 19% base India growth;
• strong chronic positioning;
• Curatio growth;
• JB cost synergies;
• high field-force productivity;
• potential deleveraging.

The market is effectively assuming that these strengths persist for years.

What is Mankind's valuation paying for?

• massive Indian prescription reach;
• 15.8% chronic growth;
• BSV specialty transformation;
• international expansion;
• margin improvement;
• rapid deleveraging.

Mankind is not inexpensive at 51x earnings.

It is simply less expensive than Torrent.

The share-price momentum gap is also large

Bull Run's September snapshot shows Torrent up approximately 40% over one year.

Mankind is down around 6%.

Torrent has already received a substantial rerating.

Mankind has not.

This raises Torrent's future execution hurdle.

What must Torrent Pharma prove?

• Base India growth should remain above the pharmaceutical market.
• JB integration should avoid meaningful brand disruption.
• 35%-plus JB margins need to prove sustainable.
• Cost synergies must convert into cash.
• Net debt to EBITDA should fall.
• Curatio needs continued high growth.
• Semaglutide supply needs stable execution.
• Earnings growth must justify a nearly 78x P/E.

What must Mankind Pharma prove?

• Domestic chronic growth should remain in the mid-teens.
• Acute recovery must remain stable.
• BSV should sustain high specialty growth.
• International revenue needs continued expansion.
• Net debt should keep falling.
• ROCE should improve as BSV matures.
• Margins should remain in the mid-20s.
• The company needs to justify a still-premium 51x P/E.

What could make Torrent outperform Mankind?

Faster synergy realization combined with deleveraging.

If JB remains a 35%-plus-margin business, India base growth stays in the mid-teens and Torrent uses cash flow to reduce acquisition debt, PAT can grow much faster than EBITDA.

The company could then begin earning a higher ROCE from the combined platform.

What could make Mankind outperform Torrent?

Multiple paths exist.

Mankind can:

• grow chronic therapies faster than the market;
• scale BSV;
• reduce debt;
• expand international revenue;
• rerate if ROCE improves.

Most importantly, it starts at a materially lower valuation.

Which has the stronger current India growth?

Torrent's base business.

It grew approximately 19% versus Mankind's broad domestic growth of approximately 10.5%.

The definitions differ because Torrent's figure excludes JB Pharma.

Which has the stronger margin?

Torrent Pharma.

Operating EBITDA margin was 33.8% versus Mankind at 26.3%.

Which has the stronger chronic opportunity?

Both, in different ways.

Torrent already has premium cardiac leadership and high productivity.

Mankind has a larger physical prescription network and is rapidly raising chronic share.

Which acquisition currently looks more financially integrated?

Mankind from a leverage perspective.

Its net debt to adjusted EBITDA has fallen to around 0.9x.

Torrent's JB integration is producing exceptional margins and synergies, but combined-company leverage remains around 2.07x.

Which stock has the stronger valuation?

Mankind Pharma.

Its approximately 51.3x P/E is materially below Torrent's 77.9x, while ROCE is currently almost identical.

Which is better: Torrent Pharma or Mankind Pharma?

Torrent Pharma currently has the stronger operating-quality profile. Its underlying business grew 17%, India grew 19%, operating EBITDA margin reached 33.8%, and JB Pharma is already producing a 35.3% margin with synergies tracking ahead of plan.

Mankind Pharma currently has the stronger valuation-and-deleveraging profile. PAT grew 29%, chronic therapies grew 15.8%, BSV is expanding the company's specialty mix, and net debt to adjusted EBITDA has fallen to approximately 0.9x.

The deciding factor is price.

Torrent trades near 78x earnings and more than 20x book value.

Mankind trades near 51x earnings and about 6.4x book.

At September 2026 valuations, Torrent is the stronger current operator but Mankind offers the more forgiving valuation. Torrent needs sustained high-teens India growth, successful JB integration and rapid deleveraging to justify its premium; Mankind needs BSV and chronic growth to lift ROCE enough to close the operating-quality gap.

Frequently asked questions